BRTX · BioRestorative Therapies, Inc.
$2.05
-0.19 (-8.48%)
At close · Oct 8
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“we believe we do not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this Quarterly Report which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$2.78M
Shares
1.27M
Volume · Oct 8
32.32K
Avg daily vol (21 sessions)
34.39K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.24
Open$2.30
Day$2.05–2.30
52W close$2.14–33.40
Avg vol 30d34K
Short int12K · 0.9% float · 1.0d
Short vol34%
Last earningsNov 12, 2025
DataJan 2020–Oct 2026
Filing10-Q · May 14
Up next
filed May 14, 2026
call held Nov 12, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$357,870
Trailing 12 months
Net income (TTM)
−$11.06M
Trailing 12 months
Revenue growth YoY
-7.3%
Year over year
Operating margin
-3,975.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+112.1%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.9%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−73%
below
Price vs 50-day avg
−36%
below
RSI (14)
28
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−18%
trailing
6-month return
−57%
trailing
YTD return
−90%
this year
Relative strength
−68%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+64% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.91% of float · ▲ +515.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
23 holders — near 3-yr high, broad support
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
+123%
Y/Y
Gross margin
415%
contracting
EPS growth
−36%
Y/Y
Free cash flow
$-10.9M
Buyback
$2.0M
remaining
Balance sheet
$20.8M
net cash
Quant / Vol
risk profile
Volatility
144%
annualized · 1-yr
Max drawdown
−94%
past year
ATR
11.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−73%
Bearish
Price vs 50-day avg
−36%
Bearish
RSI (14)
28
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+64% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.91% of float · ▲ +515.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
23 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $33
vs 200-day avg -73%
vs 50-day avg -36%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BRTX
this stock
BioRestorative Therapies, Inc.
|
$2.78M | — | +122.8% | — | 0.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.5% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.44B | +566.3% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.40B | -3.9% | +20.8% | 18.4 | 2.5% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BRTX | -3.9% | -18.3% | -56.9% | -3.9% | -90.5% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | -5.8% | -20.2% | -67.7% | -5.8% | -104.5% |
Capital returns
Buyback program
· as of Mar 31, 2026
Authorized
$2.00M
Spent (derived)
$0
Remaining
$2.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.